抗英夫利西单抗抗体加速清除而剂量强化可逆转免疫原性并恢复临床应答在儿童克罗恩病中
这项多中心前瞻性队列研究纳入78例儿童克罗恩病患者,首年治疗期间采集660次输注的血清英夫利西单抗/抗英夫利西单抗抗体浓度。68%(53/78)患者检出抗英夫利西单抗抗体,中位浓度76 ng/mL,抗体阳性患者英夫利西单抗清除率更高(P < 0.001);剂量调整使37.5%(12/32)患者抗体消失并恢复英夫利西单抗浓度和清除率。
要点
- 68%(53/78)儿童克罗恩病患者检出抗英夫利西单抗抗体,中位浓度76 ng/mL。
- 抗体阳性患者英夫利西单抗清除率高于抗体阴性患者(P < 0.001)。
- 剂量调整使37.5%(12/32)患者抗体消失并恢复英夫利西单抗浓度和清除率。
核心结论
- 在真实世界队列中,低至23 ng/mL的抗英夫利西单抗抗体即影响药物清除。
- 数据提示对低水平抗英夫利西单抗抗体进行剂量优化可改善英夫利西单抗清除并防止失应答。
研究设计与样本
- 多中心前瞻性队列研究,纳入78例儿童克罗恩病患者,随访1年,采集660次输注的血清英夫利西单抗/抗英夫利西单抗抗体浓度。
- 临床医生对研究实验室结果设盲。
主要发现
- 68%(53/78)患者检出抗英夫利西单抗抗体,中位浓度76 ng/mL(范围23-1828)。
- 73.6%(39/53)患者最大抗英夫利西单抗抗体浓度<200 ng/mL。
- 抗体阳性患者中位英夫利西单抗清除率高于抗体阴性患者(P < 0.001),失应答者清除率更高。
- 多变量回归中,中性粒细胞CD64比值>6和起始剂量<7.5 mg/kg独立预测抗英夫利西单抗抗体,而HLA-DQA1*05存在与否不预测。
- 剂量调整使37.5%(12/32)患者抗英夫利西单抗抗体消失,伴英夫利西单抗浓度和清除率恢复。
关键数值与推荐
- 抗英夫利西单抗抗体中位浓度76 ng/mL(范围23-1828)。
- 最大抗英夫利西单抗抗体浓度<200 ng/mL者占73.6%(39/53)。
- 中性粒细胞CD64比值>6和起始剂量<7.5 mg/kg独立预测抗英夫利西单抗抗体。
- 最大抗英夫利西单抗抗体水平≤99 ng/mL预测抗体消失,曲线下面积0.80(95% CI 0.64-0.96)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibodies to infliximab (ATI) are associated with secondary loss of response and increased risk for drug reactions. Limited studies have associated ATI with increased infliximab clearance. AIMS: We assessed the impact of ATI on infliximab clearance and loss of response in an inception paediatric Crohn's disease cohort with 1-year follow-up. METHODS: This multi-centre prospective cohort study collected peak and trough serum infliximab/ATI concentrations from 660 infusions (78 patients) during the first year of therapy. Clinicians were blinded to these research labs. The primary outcome was the difference in infliximab clearance between ATI-positive (ATI) and ATI-negative (no-ATI) patients. Secondary outcomes included pre-treatment predictors of ATI (including HLA-DQA1 genotyping). Clinical remission, loss of response and infliximab clearance were compared between pre-ATI, during ATI and following ATI resolution with MANOVA. Time to ATI was calculated by Cox proportional Hazards model. RESULTS: ATI were detected in 68% (53/78) patients with a median concentration of 76 ng/mL (range 23-1828). Maximum ATI concentration was <200 ng/mL in 73.6% (39/53). Median clearance in ATI patients was higher (with higher clearance if loss of response), compared to no-ATI patients (P < 0.001). Neutrophil CD64 ratio >6 and starting dose <7.5 mg/kg independently predicted ATI in multivariable regression, while HLA-DQA1*05 presence did not. Dose adjustment resolved ATI in 37.5% (12/32) patients with concomitant infliximab concentration and clearance recovery. A maximum ATI level of ≤99 ng/mL predicted ATI resolution (area under the receiver operating curve 0.80 [95% CI 0.64-0.96]). CONCLUSIONS: In this real-world cohort, ATI as low as 23 ng/mL impacted drug clearance. Our data suggest that dose optimisation for low-level ATI can improve infliximab clearance and prevent loss of response.
引用
- Colman RJ, Xiong Y, Mizuno T, et al. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Aliment Pharmacol Ther. 2021. PMID: 34935161. doi:10.1111/apt.16733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。